The estimated Net Worth of Keith Katkin is at least $975 mil dollars as of 6 October 2022. Mr. Katkin owns over 29,899 units of Syndax Pharmaceuticals Inc stock worth over $753,263 and over the last 9 years he sold SNDX stock worth over $0. In addition, he makes $221,246 as Independent Director at Syndax Pharmaceuticals Inc.
Sign up
Mr. Katkin SNDX stock SEC Form 4 insiders trading
Keith has made over 4 trades of the Syndax Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 29,899 units of SNDX stock worth $245,172 on 6 October 2022.
The largest trade he's ever made was exercising 180,000 units of Syndax Pharmaceuticals Inc stock on 19 February 2020 worth over $694,800. On average, Keith trades about 9,824 units every 30 days since 2015. As of 6 October 2022 he still owns at least 41,117 units of Syndax Pharmaceuticals Inc stock.
You can see the complete history of Mr. Katkin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keith Katkin biography
Keith A. Katkin CPA serves as Independent Director of the Company. Mr. Katkin is a Class III director who has served as a member of our board of directors since March 2017. Since September 2017, Mr. Katkin has served as the Chief Executive Officer and a member of the board of directors of Urovant Sciences Ltd., a public biopharmaceutical company focused on developing novel therapies for urologic conditions. From March 2007 through January 2016, he was President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he led the execution of the company’s sale to Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Katkin joined Avanir as the Senior Vice President of Sales and Marketing and a member of Avanir’s executive management team. Mr. Katkin was responsible for creating and executing the plan that led to the approval of Nuedexta and the company’s growth to commercial success. Prior to joining Avanir, Mr. Katkin served as the Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson. Additionally, Mr. Katkin’s employment experience includes leadership roles at InterMune, Amgen and Abbott Laboratories. Mr. Katkin currently serves as a director at several public companies, including Urovant Sciences, Inc., Novus Therapeutics, Inc. (Non-Executive Chairman) and Rigel Pharmaceuticals, Inc. Mr. Katkin has an M.B.A. from the Anderson School at UCLA and earned a B.S. in Business and Accounting from Indiana University. Mr. Katkin is also a licensed Certified Public Accountant.
What is the salary of Keith Katkin?
As the Independent Director of Syndax Pharmaceuticals Inc, the total compensation of Keith Katkin at Syndax Pharmaceuticals Inc is $221,246. There are 7 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.
How old is Keith Katkin?
Keith Katkin is 48, he's been the Independent Director of Syndax Pharmaceuticals Inc since 2017. There are 15 older and 2 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.
What's Keith Katkin's mailing address?
Keith's mailing address filed with the SEC is 300 PROFESSIONAL DRIVE, , GAITHERSBURG, MD, 20879.
Insiders trading at Syndax Pharmaceuticals Inc
Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin y Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.
What does Syndax Pharmaceuticals Inc do?
syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.
What does Syndax Pharmaceuticals Inc's logo look like?
Complete history of Mr. Katkin stock trades at Novus Therapeutics Inc, Rigel Pharmaceuticals, Syndax Pharmaceuticals Inc, Emergent Biosolutions Inc y Urovant Sciences Ltd
Syndax Pharmaceuticals Inc executives and stock owners
Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Michael Metzger,
President, Chief Operating Officer, Director -
Briggs Morrison,
Chief Executive Officer, Director -
Dr. Briggs W. Morrison M.D.,
CEO & Director -
Michael A. Metzger M.B.A.,
Pres, COO & Director -
Michael Meyers,
Senior Vice President, Chief Medical Officer -
Dennis Podlesak,
Independent Chairman of the Board -
Pierre Legault,
Independent Director -
Keith Katkin,
Independent Director -
William Meury,
Independent Director -
Fabrice Egros,
Independent Director -
Jennifer Jarrett,
Independent Director -
Peter Ordentlich,
Chief Scientific Officer -
Luke Albrecht,
Senior Vice President, General Counsel, Secretary -
Daphne Karydas,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer -
Dr. Edward A. Sausville M.D., Ph.D.,
Advisor -
Dr. Michael L. Meyers M.D., Ph.D.,
Chief Medical Officer & Sr. VP -
Luke J. Albrecht,
Sr. VP, Gen. Counsel & Sec. -
Alexander Nolte,
Interim Principal Financial Officer, VP & Chief Accounting Officer -
Dr. Michael Downes Ph.D.,
Co-Founder -
Dr. Ronald M. Evans Ph.D.,
Co-Founder, Advisor and Chair of Scientific Advisory Board -
Dr. Richard A. Heyman Ph.D.,
Co-Founder -
Dr. Peter Ordentlich B.Sc., Ph.D.,
Co-Founder & Chief Scientific Officer -
Martin H. Jr. Huber,
-
Neil Gallagher,
President, Head of R&D -
Luke Evnin,
Director -
Henry Chen,
-
Partners L P/Ilbiotechnolog...,
-
Steve M Sabus,
Chief Commercial Officer -
Ivor Royston,
Director -
Viii Associates, L.P.Blair ...,
-
Vi Associates, L.P.Blair Ja...,
-
Partners Vi, L.P.Blair Jame...,
-
George W. Jr. Sledge,
-
Bio Ventures Iv Qp Lp Scopa...,
-
Partners Viii, L.P.Blair Ja...,
-
Kim P. Kamdar,
Director -
Richard P Shea,
Chief Financial Officer -
Alexander Nolte,
Chief Accounting Officer -
Catherine Madigan,
Chief Medical Officer -
Keith A. Goldan,
Chief Financial Officer